All Stories

  1. Service delivery, behavioural, and self-management interventions for children with epilepsy
  2. Service delivery, behavioural, and self-management interventions for adults with epilepsy
  3. Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis
  4. Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses
  5. Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
  6. Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15
  7. Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
  8. Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
  9. Service delivery, behavioural, and self-management interventions for adults with epilepsy
  10. Service delivery, behavioural, and self-management interventions for children with epilepsy
  11. Health effects of liquid and gaseous fuels for household energy use: Systematic evidence mapping
  12. Health Effects of Liquid and Gaseous Fuels for Household Energy Use: Systematic Evidence Mapping
  13. Care delivery and self-management strategies for children with epilepsy
  14. Are cleaner cooking solutions clean enough? A systematic review and meta-analysis of particulate and carbon monoxide concentrations and exposures
  15. A systematic review of health state utility values for thyroid cancer
  16. Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
  17. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation
  18. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine
  19. Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
  20. Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
  21. Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis
  22. Care delivery and self-management strategies for children with epilepsy
  23. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
  24. An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review
  25. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
  26. The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation
  27. Care delivery and self management strategies for adults with epilepsy
  28. Care delivery and self management strategies for children with epilepsy
  29. Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis
  30. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
  31. Economic evaluations of personalized medicine: existing challenges and current developments
  32. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
  33. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis
  34. Deferasirox for managing iron overload in people with myelodysplastic syndrome
  35. Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal
  36. Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer
  37. Deferasirox for managing transfusional iron overload in people with sickle cell disease
  38. Allopurinol for the treatment of chronic kidney disease: asystematic review
  39. Are health technology assessments of pharmacogenetic tests feasible? A case study ofCYP2D6testing in the treatment of breast cancer with tamoxifen
  40. Deferasirox for managing iron overload in people with thalassaemia
  41. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
  42. Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE
  43. Deferasirox for managing iron overload in people with myelodysplastic syndrome
  44. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
  45. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses
  46. Deferasirox for managing transfusional iron overload in people with sickle cell disease
  47. Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
  48. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
  49. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
  50. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention
  51. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation
  52. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck
  53. Rituximab for the treatment of rheumatoid arthritis
  54. Providing patients with information on pharmacogenetic testing
  55. Providing patients with information on pharmacogenetic testing
  56. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation
  57. Deferasirox for managing transfusional iron overload in people with sickle cell disease
  58. Deferasirox for managing iron overload in people with thalassaemia
  59. Deferasirox for managing iron overload in patients with myelodysplastic syndrome
  60. So many filters, so little time: the development of a search filter appraisal checklist
  61. A prospective health impact assessment of the Merseyside Integrated Transport Strategy (MerITS)
  62. ALCOHOL HOME DETOXIFICATION: A LITERATURE REVIEW